A Mechanistic, Stochastic Model Helps Understand Multiple Sclerosis Course and Pathogenesis
Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience...
Transcript of Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience...
![Page 1: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/1.jpg)
Multiple Sclerosis—Pathogenesis, diagnosis, and treatment
Joshua Chalkley DO MS
Assistant Professor of Neurology
Marcus Neuroscience Institute
Assistant Professor of Neurology Florida Atlantic University Adjunct faculty
![Page 2: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/2.jpg)
Multiple sclerosis (MS)
an inflammatory, demyelinating, neurodegenerative disease of the central nervous system (CNS).
INFLAMMATION - Is this the cause of or a reaction to the axonal
demyelination and injury?
- Initialing factor of the disease is unknown, but an aberrant immune response plays a critical role.
![Page 3: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/3.jpg)
Multiple sclerosis (MS)
All FDA-approved MS therapies alter immune function and reduce inflammation
![Page 4: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/4.jpg)
Epidemiology
Affects female 2-3X as often as men
Age of onset: rare in pediatric population; risk increases from adolescence to AGE 35, then decreases
Rarely diagnosed after age 65 years
![Page 5: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/5.jpg)
Epidemiology
Uncommon in equatorial climates
-Prevalence increase with northern distance from equator.
-North/south gradient seen within North America, Europe, and Japan, suggesting unidentified environmental risk factor
Strong associations:
-VITAMIN D deficiency, infectious agent (EBV)
![Page 6: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/6.jpg)
Latitude factors - Residence for first 15 years of life determines risk
![Page 7: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/7.jpg)
Genetic component
Twin studies: Concordance rates in monozygotic twins = 25% vs. 5% in dizygotic twins.
Rate of fraternal twins is similar to that of first-degree relatives of patients with MS. Several genes (>12) that make individuals susceptible to MS have been discovered.
![Page 8: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/8.jpg)
Etiology
Unknown
Appears to be a combination of environmental factors (including Vitamin D deficiency, EBV exposure) in genetically predisposed individuals.
![Page 9: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/9.jpg)
Pathology
Plaques – areas of damaged myelin with inflammatory infiltrates
Deep white matter
Near ventricles, corpus callosum, optic nerve
Spinal cord, brainstem, cerebellar peduncles
Some cortical involvement
![Page 10: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/10.jpg)
Pathology
Acute
Demyelination
Axon-sparing
Perivascular infiltrate
Perivascular edema
Activated astrocytes and hyperactive oligo’s at border
![Page 11: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/11.jpg)
Microscopically one sees the pallor on an H&E section in the old plaque because
the myelin which stains pink on this stain is absent in areas of demyelination.
Axons are relatively preserved and astrocytes will be found in the lesion. They
respond to the loss of myelin.
![Page 12: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/12.jpg)
![Page 13: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/13.jpg)
THIS HIGH CERVICAL CORD LESION IS STAINED BLACK FOR MYELIN. THIS LARGE DEMYELINATED PLAQUE AFFECTS THE POSTERIOR COLUMNS, WHICH CARRY PROPRIOCEPTIVE OR POSTIONAL SENSE.
![Page 14: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/14.jpg)
Pathology
Chronic
Oligodendrocytes disappear
Axonal degeneration
Astrocyte hypertrophy and hyperplasia=sclerosis
*Capacity to rebound from acute attacks diminishes with disease duration and age.
![Page 16: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/16.jpg)
![Page 17: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/17.jpg)
Presentation Initial focal neurologic symptoms (weakness, sensory changes, visual loss) develop over hours to days
Optic Neuritis is the most common presentation 30%
May be acute vs. insidious, mild vs. severe (clinic vs. hospital presentation)
MS can present with almost anything, have to keep an open mind
![Page 18: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/18.jpg)
Presentation
Fatigue and general malaise often proceed first focal attack
MS patients visit the doctor more frequently than controls two years proceeding MS diagnosis
General feeling that something is wrong
![Page 19: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/19.jpg)
Presentation - Frequency of Symptoms at Disease Onset:
Sensory changes 34%
Weakness 22%
Vision loss 13%
Ataxia 11%
Diplopia 8%
![Page 20: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/20.jpg)
Frequency of Symptoms During Entire Disease Course:
Weakness 89%
Sensory disturbance 87%
Ataxia 82%
Bladder dysfunction 71%
Fatigue 57%
Cramps 52%
Diplopia 51%, Vision loss 49%
Bowel dysfunction 42% Other: dysarthria, vertigo, facial pain, memory, headache, psychiatric sx, hearing loss, facial weakness, dysphagia
![Page 21: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/21.jpg)
Presentation - History
HISTORY: ask about prior focal neurological deficits with CNS localization
Exclude other diagnoses based on history (time course, symptoms, remissions)
Exacerbations with subsequent resolution of symptoms (i.e. remissions)
![Page 22: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/22.jpg)
Presentation - History
ASSOCIATED SYMPTOMS:
- Fatigue
- Heat sensitivity (Uhthoff’s phenomenon-vision disturbance assoc. with heat)
- Lhermitte’s sign – electrical sensation down spine with neck movement
- Autonomic symptoms (bowel/bladder/sexual dysfunction)
- pain, muscle cramps
- cognitive or psychiatric symptoms
![Page 23: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/23.jpg)
Physical Examination: Mental Status
MS, CNs, Motor, Sensory, Coordination
Affect
Depression screen (PHQ-9, BDI-2)
Memory, cognition (MMSE, MOCA)
![Page 24: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/24.jpg)
Physical Examination: Cranial Nerves
MS, CNs, Motor, Sensory, Coordination
Optic neuritis Red swollen disc followed by pallor vs.
optic atrophy (chronic)
Decreased visual acuity, central scotoma, color desaturation (Ishihara color chart)
Marcus-Gunn pupil (APD)
Disconguate gaze (ex. INO)
Facial dysesthesia, loss of taste, hearing loss, nystagmus, dysphagia, dysarthria
![Page 25: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/25.jpg)
Physical examination: Motor
MS, CNs, Motor, Sensory, Coordination
Strength: Paresis
Tone: Spasticity
Reflexes: Hyperactive reflexes (ex. brisk patellar reflexes, cross-adductors sign)
-clonus in the ankles, Babinski sign
**ALL UPPER MOTOR NEURON SIGNS**
![Page 26: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/26.jpg)
Physical examination: Sensory
MS, CNs, Motor, Sensory, Coordination
Lhermitte’s sign – tested objectively with passive neck flexion
Impaired proprioception and vibration(Posterior columns commonly affected)
**ROMBERG**
Impaired pain, temperature, or light touch
![Page 27: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/27.jpg)
Physical examination: Coordination
MS, CNs, Motor, Sensory, Coordination
Ataxia (appendicular or truncal)
Gait
Tremor
Nystagmus (brainstem vs. cerebellar)
Dysarthria (brainstem vs. cerebellar)
![Page 28: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/28.jpg)
Diagnosis
![Page 29: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/29.jpg)
Hallmark: Waxing and waning neurological deficits that localize to the CNS
No single test can diagnose MS.
Diagnosis relies on recognition of clinical patterns of disease AND exclusion of possible mimics.
Diagnosis is supported by history, exam, MRI brain and spine, analysis of CSF, and evoked-potentials.
![Page 30: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/30.jpg)
Diagnosis
CNS LESIONS SEPERATED BY SPACE AND TIME
OPTIC NERVES, BRAIN, SPINAL CORD
Example: Patient with optic neuritis, who 1) initial MRI shows other MS plaques OR 2) several months later develops cerebellar ataxia.
This represents 2 spaces, 2 times.
![Page 31: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/31.jpg)
Cree, Bruce A. C. CONTINUUM: Lifelong Learning in Neurology Volume 16(5) Multiple Sclerosis October 2010 pp 19-36
![Page 32: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/32.jpg)
Summary of criteria:
If one of five sets of criteria are fulfilled and other etiologies are excluded, the diagnosis is MS.
If suspicious, but the criteria are not completely met, the diagnosis is “possible MS.”
If another diagnosis arises that better explains the entire clinical presentation, then the diagnosis is “not MS.”
![Page 33: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/33.jpg)
Criteria Update
2017 updated criteria
Major change included evaluation of spinal fluid
Can use asymptomatic and symptomatic lesions
Site of lesion can include cortical lesions
![Page 34: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/34.jpg)
Relapsing Remitting: 85% of patients follow this course, at least initially.
![Page 35: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/35.jpg)
Imaging
Abnormalities Periventricular WM lesions
“Dawson’s fingers”
Corpus callosum thinning/scalloping
Infratentorial lesions – pons, cerebellar peduncles, white matter adjacent to the 4th ventricle
Atrophy
Contrast enhancement – evidence of ‘active’ disease (i.e. inflammation)
![Page 36: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/36.jpg)
Physical examination
![Page 37: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/37.jpg)
![Page 38: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/38.jpg)
![Page 39: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/39.jpg)
CSF examination
Perform LP when additional information is needed to confirm the diagnosis.
- MRI is normal
- History, exam, or imaging is concerning for another disease process (infection, inflammatory, vasculitis)
CSF is abnormal in 85-90% of patients with MS
![Page 40: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/40.jpg)
CSF Analysis
Opening pressure – normal
WBC: 5-20 lymphocytes
Protein 40-60
Evidence of intrathecal synthesis of gamma globulins:
- Oligoclonal bands elevated in 90%
- IgG synthesis rate >3 in 80-90%
- IgG index >0.7 in 90%
Myelin basic protein elevated (~2 weeks)
![Page 41: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/41.jpg)
Evoked potentials
Visual Evoked Potentials (VEP)
Somatosensory Evoked Potentials (SSEP)
Brainstem/Auditory Evoked Potentials (BAEP)
Characteristic findings suggest demyelination by showing asymmetric, delayed response or conduction block. May remain abnormal for years after an acute exacerbation
In 75% of patients with MS, VEPs are abnormal.
![Page 42: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/42.jpg)
Visual Evoked Potentials
![Page 43: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/43.jpg)
Differential Diagnosis
Idiopathic CNS Demyelnating Diseases: Acute disseminated encephalomyelitis(ADEM), Neuromyelitis optica (Devic’s)
Systemic Autoimmune diseases: Lupus (SLE), Sjogren syndrome, Sarcoidosis)
Chronic infections {most common:HTLV 1 and 2, HIV, syphilis, JC virus (PML)}
![Page 44: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/44.jpg)
Differential Diagnosis (cont.)
Vascular diseases (stroke, leukoariosis, primary CNS vasculitis, Susac disease)
Malignancies (primary CNS lymphoma, paraneoplastic syndromes)
Nutritional (Vitamin B12 deficiency – dorsal columns)
Somatization, conversion disorders
![Page 45: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/45.jpg)
Treatment
Require ongoing treatment
Immunomodulation to decrease frequency and severity of recurrence
Treatment of acute exacerbation
Symptomatic treatment of associated MS symptoms (fatigue, spasticity, etc.)
![Page 46: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/46.jpg)
Long-term Treatment: Disease Modifying
Therapies
![Page 47: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/47.jpg)
Disease Modifying therapy
Wide variety of medication
No perfect treatment
Reduce inflammation and prevent attacks
Some of the newer drugs may also aid in preventing progression
![Page 48: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/48.jpg)
Disease Modifying Therapies (DMTs) – FDA Approved Agents
Inteferon Beta
injections
Reduce antigen presentation and T cell response
Improve relapse rates and disability
Safe and effective
Have significant side effects
Psychiatric symptoms flu like illness can affect the liver and white blood cells
![Page 49: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/49.jpg)
Glatiramer Acetate
Injections given daily or three times weekly
4 amino Acids found in myelin basic protein
Disease Modifying Therapies (DMTs)
![Page 50: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/50.jpg)
Pros
Safe
Effective
No serious side effects
![Page 51: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/51.jpg)
Cons
Daily injection
Painful
Injection site reactions
![Page 52: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/52.jpg)
Natalizumab
Blocks T cell Migration into the CNS
Approved for inflammatory bowel disease and MS
Very effective in the treatment of MS
Monthly infusion
![Page 53: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/53.jpg)
Pros
Very effective
Tolerated well
Overall good safety profile
![Page 54: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/54.jpg)
Cons
PML
JCV virus testing before initiation of treatment and routine monitoring throughout treatment
Risk stratification for treatment
![Page 55: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/55.jpg)
Disease Modifying Therapies (DMTs)
Fingolimod .
- once daily medication
- reduces exacerbation frequency and delay accumulation of physical disability
Sphingosine-1-phosphate receptor modulator
Traps lymphocytes in lymph tissue
![Page 56: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/56.jpg)
Pros
Very effective
Likely most effective of the oral medications
Minimal reported side effects
Overall safe
![Page 57: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/57.jpg)
Cons
Difficult to initiate
Lymphopenia
Can affect the liver
Slows heart rate
PML and other rare infections and cancer
Karposi Sarcome, skin cancer, Varicella
![Page 58: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/58.jpg)
Dimethyl Fumerate
Twice day oral medication
Likely works by transitioning T cells into more inert state, exact mechanism is not known
Effective
![Page 59: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/59.jpg)
Pros
Effective
Oral medication
Easy to initiate therapy
![Page 60: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/60.jpg)
Cons
GI upset
flushing
Can cause lymphopenia
Can affect the liver
PML- handful of cases likely related to overall lymphocyte count
![Page 61: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/61.jpg)
Other medications
There are more medications including but you will not be tested on these so we will hold them for now
Terflunimide- approved
Alemtuzumab-approved
Rituxumab- trials showing efficacy
Ocrelizumab-
Daclizumab- recently pulled from the market
![Page 62: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/62.jpg)
Acute Exacerbation: To treat or
not to treat an exacerbation?
Methylprednisolone 1000 mg x 3-5 days
- No evidence of change in disease course, but may
shorten acute exacerbation.
If not responsive and exacerbation is severe, plasma exchange can be beneficial.
![Page 63: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/63.jpg)
Symptomatic Treatment
MS symptoms can cause disability from workforce and social isolation.
Focusing on symptom management can significantly improve quality of life.
![Page 64: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/64.jpg)
Effective symptomatic treatments for:
Gait impairment – Ampyra (dalfampridine-SR) - improvement in walking speed
Disabling spasticity
Pain, severe facial pain
Disabling fatigue
Heat-induced fatigue and vision loss (Uhtoff phenomenon)
Symptom Management
![Page 65: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/65.jpg)
Symptom Management (cont.)
Depression, anxiety
Pseudobulbar affect
Bladder spasticity (urgency, frequency, incontinence)
Bladder hyptonicity
Erectile dysfunction
![Page 66: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/66.jpg)
Symptomatic treatment
Also encourage non-medication treatment with:
- Physical, occupational, and speech therapy
- Exercise, including stretching, swimming, yoga, tai-chi
- Psychotherapy, meditation for depression and anxiety
![Page 67: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/67.jpg)
Better Prognosis
Females
Predominantly sensory
Complete or near-complete resolution of symptoms after relapse
![Page 68: Multiple Sclerosis—Pathogenesis, diagnosis, and treatmentweb.brrh.com/msl/Practical Neuroscience for the Non... · Multiple Sclerosis— Pathogenesis, diagnosis, and treatment Joshua](https://reader034.fdocuments.in/reader034/viewer/2022050105/5f433b96894083271175538b/html5/thumbnails/68.jpg)
Worse Prognosis
Males, older age of onset
Multifocal
Progression
Ability to recover from exacerbations lessens as the disease progresses.